International Dental Journal · Oct 2026

Enhanced Anticancer Potential of Nano-Metformin in HEp-2 Cell Line

By Mohammed S, Raafat S, Abdollah M et al.

AIM or PURPOSE to evaluate the hypothesis that the encapsulation of Metformin, an oral antidiabetic drug, in nanospanlastics will enhance its anticancer potential against HEP-2 cancer cells. MATERIALS and METHODS Metformin-loaded nanospanlastics were successfully fabricated and characterized. Cytotoxicity of Metformin and Nano-Metformin on HEP-2 cancer cells was evaluated using MTT assay. Cell cycle analysis was done using Flow Cytometry and eventually, apoptotic activity was evaluated using Western blotting to measure the expression of BAX and BCL-2 genes and RT-qPCR to measure the fold change for caspase-3 −8, and − 9 levels as well as cyclin D1 and mTOR levels. RESULTS Nano-Metformin significantly decreased the percentage of live cells compared to Metformin. Moreover, Nano-Metformin downregulated BCL-2 and upregulated BAX protein. RT-qPCR revealed that Nano-Metformin caused a significant fold increase in caspase-3, −8, and − 9 levels as well as a significant fold decrease in cyclin D1 and mTOR levels compared to the free drug. CONCLUSIONS Nano-Metformin demonstrated enhanced anticancer activity against HEp-2 cell line by significantly reducing cell viability and inducing apoptosis, highlighting its potential as a promising therapeutic approach for head and neck squamous cell carcinoma.

doi.org/10.1016/j.identj.2026.110030Interventions

AgingResearch.News